Dakshidin Corporation, Inc.
Dakshidin Corporation, Inc.
Your view on DKSC
Overview
What the company does, where it operates, and who runs it.
About Dakshidin Corporation, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Christopher Robin Haigh
- Headquarters
- 2250 NW 114th Avenue, Miami, FL, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Christopher Robin Haigh
- Headquarters
- 2250 NW 114th Avenue, Miami, FL, US
Dakshidin Corporation, Inc., through its subsidiaries, operates as a CBD/cannabis-based medical product company. It cultivates cannabis; and operates an online sales portal for CBD products. The company also manages distribution channel programs in the retail distribution, reselling, and direct sales market segments.
Dakshidin Corporation, Inc. was formerly known as Avrada, Inc. and changed its name to Dakshidin Corporation, Inc. in February 2007. The company is based in Miami, Florida with additional offices in Las Vegas, Nevada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Dakshidin Corporation, Inc., and the rating behind it. DKSC last traded at $0.0005; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Dakshidin Corporation, Inc.. Starting points for Dakshidin Corporation, Inc.: beta -1.23 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Dakshidin Corporation, Inc.. Dakshidin Corporation, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Dakshidin Corporation, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Dakshidin Corporation, Inc.. Dakshidin Corporation, Inc. has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Dakshidin Corporation, Inc. valued side by side against its closest peers. Dakshidin Corporation, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Dakshidin Corporation, Inc., and how their positions are changing. At a $2.2M market value, institutional positions materially move Dakshidin Corporation, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Dakshidin Corporation, Inc. executives and directors. Shares of Dakshidin Corporation, Inc. have traded between $0.0001 and $0.0008 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Dakshidin Corporation, Inc.. Dakshidin Corporation, Inc. is a $2.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Dakshidin Corporation, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Dakshidin Corporation, Inc.. Coverage tracks Dakshidin Corporation, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.